Last reviewed · How we verify
Clostridium Butyricum Tablets
Clostridium Butyricum Tablets is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently in Phase 2 development. Also known as: Cisplatin, Gemcitabine.
At a glance
| Generic name | Clostridium Butyricum Tablets |
|---|---|
| Also known as | Cisplatin, Gemcitabine |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
- PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) (NA)
- The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function (NA)
- Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- Clostridium Butyricum in Stenosing Crohn's Desease (PHASE1, PHASE2)
- Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study (NA)
- Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D (NA)
- PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clostridium Butyricum Tablets CI brief — competitive landscape report
- Clostridium Butyricum Tablets updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI
Frequently asked questions about Clostridium Butyricum Tablets
What is Clostridium Butyricum Tablets?
Clostridium Butyricum Tablets is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University.
Who makes Clostridium Butyricum Tablets?
Clostridium Butyricum Tablets is developed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).
Is Clostridium Butyricum Tablets also known as anything else?
Clostridium Butyricum Tablets is also known as Cisplatin, Gemcitabine.
What development phase is Clostridium Butyricum Tablets in?
Clostridium Butyricum Tablets is in Phase 2.
Related
- Manufacturer: The First Affiliated Hospital with Nanjing Medical University — full pipeline
- Also known as: Cisplatin, Gemcitabine
- Compare: Clostridium Butyricum Tablets vs similar drugs
- Pricing: Clostridium Butyricum Tablets cost, discount & access